Related Experiment Video

Updated: May 17, 2026

Generation of Scaffold-free, Three-dimensional Insulin Expressing Pancreatoids from Mouse Pancreatic Progenitors In Vitro
09:33

Generation of Scaffold-free, Three-dimensional Insulin Expressing Pancreatoids from Mouse Pancreatic Progenitors In Vitro

Published on: June 2, 2018

[Growth and puberty in type 1 diabetes mellitus - experience from a pediatric endocrinology unit]

Catarina Timóteo1, Susana Castanhinha, Carolina Constant

  • 1Serviço de Pediatria, Centro Hospitalar Leiria/Pombal, Leiria, Portugal.

Acta Medica Portuguesa
|October 20, 2012
PubMed

Insights

Type 1 Diabetes Mellitus (T1DM) in children can impact growth. While higher HbA1c levels may slow growth velocity and pubertal height gain, final adult height is generally not compromised in pediatric patients.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Child Growth and Development

Context:

  • Type 1 Diabetes Mellitus (T1DM) is a common endocrine-metabolic condition in children.
  • T1DM is associated with potential complications affecting growth and development.
  • Pediatric endocrine outpatient clinics manage T1DM patients, monitoring growth and puberty.

Purpose:

  • To investigate the relationship between metabolic control (HbA1c) and disease duration with growth and pubertal development in children with T1DM.
  • To assess the impact of T1DM management on final height attainment.

Summary:

  • A retrospective analysis of 39 T1DM patients diagnosed before puberty.
  • Results indicated a trend where higher HbA1c levels correlated with reduced growth velocity and pubertal height gain, though not statistically significant.
  • Despite initial height differences and some loss during puberty, patients achieved normal final heights consistent with their genetic potential.

Impact:

  • Provides insights into the long-term growth outcomes for children with T1DM.
  • Highlights the importance of metabolic control in optimizing growth trajectory during childhood and adolescence.
  • Informs clinical practice regarding growth monitoring and management strategies in pediatric T1DM.
Abstract

More Related Videos

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-1906:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Related Concept Videos

Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...